Age-Related Macular Degeneration

The clinical trials have purposefully strict inclusion and exclusion criteria to control the variables that might affect the outcomes of an intervention.

Novel pharmacotherapies for retinal vascular diseases are pursuing the dual goal of increased efficacy and longer duration of action.

SEATTLE — In this video, Esther M. Bowie, MD, discusses the results of the TRUCKEE study presented at the ASRS annual meeting by Emmanuel Y. Chang, MD, PhD, FACS, FASRS.

SEATTLE — In this video, Esther M. Bowie, MD, discusses findings presented at the ASRS annual meeting on the efficacy and safety of ranibizumab biosimilars.The study, which evaluated 3,964 patients, was presented by Carl C. Awh, MD, FASRS.

Izervay met its primary objective of slowing geographic atrophy growth compared with sham at 24 months in the phase 3 GATHER2 clinical trial, according to a press release from Astellas Pharma.

SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Carl D. Regillo, MD, discusses AVD-104, a sialic acid-coated nanoparticle under investigation for the treatment of nonexudative age-related macular degeneration.

The American Society of Retina Specialists annual meeting featured study results and research in age-related macular degeneration.

SEATTLE — In this video, Esther M. Bowie, MD, discusses the results of the phase 3 PULSAR trial presented at the ASRS annual meeting.

The FDA approved Eylea HD, an 8 mg aflibercept injection, to treat wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy, according to a press release from Regeneron.

The European Medicines Agency accepted the marketing authorization application for avacincaptad pegol, according to a press release from Astellas Pharma.